Healthcare company Magnolia Medical Technologies recently revealed promising results from an in-vitro study demonstrating that the Steripath® Initial Specimen Diversion Device® (ISDD®) could significantly enhance the accuracy of blood cultures drawn from existing central venous catheters (CVCs). This innovation may change the landscape of infection detection, particularly for severely ill patients dependent on CVCs.
The investigators from the University of Nebraska Medical Center (UNMC) conducted this groundbreaking study, published in a reputable peer-reviewed medical journal, Infection Control & Hospital Epidemiology. Their empirical work, titled ‘In Vitro assessment of effect of initial specimen diversion device on detection of central venous catheter contamination or colonization,’ symbolizes the inaugural published assessment of a closed-system, designed diversion device for such use.
The researchers compared blood cultures drawn using standard procedures versus those using the Steripath ISDD in a simulated model of CVC colonization and contamination. Results revealed that the use of Steripath ISDD significantly improved the detection rate of colonized CVCs to 100% and reduced false-positive cultures by 56%. The study accentuates the possible influential role of the Steripath ISDD family in amplifying diagnostic precision for bloodstream infection detection.
Dr. Mark E. Rupp from UNMC applauded the promising evidence the study has provided, highlighting its potential value for patients reliant on blood culture from CVCs. The improved diagnostic accuracy means that clinicians may make more informed decisions, potentially reducing unwarranted antibiotic use, and ultimately improving patient outcomes. Further investigation through a prospective clinical trial is warranted, based on these impressive preliminary results.
The Steripath ISDD’s profound impact on hospital quality metrics, antibiotic stewardship programs, and reimbursement under CMS’s Value-Based Purchasing (VBP) Program has been emphasized by previous clinical findings. The device has successfully demonstrated its potential to reduce blood culture contamination to 0%, significantly curtailing false-positive central line-associated bloodstream infections.
The study presents a potential paradigm shift in the differentiation of contamination events from true bloodstream infections, especially when they are drawn from a CVC. The Steripath ISDD technology is potentially a valuable tool in improving the diagnostic legitimacy for this critical procedure.
Magnolia Medical remains dedicated to revolutionizing blood culture collection methodologies by developing clinically proven, scientifically validated innovations. Partnering with numerous leading healthcare institutions, the company continues to expand nationwide access to Steripath ISDD technology.
Steripath is an FDA-approved, all-in-one developed device that has proven effective in reducing blood culture contamination. It has been used by over 500 U.S. hospitals and healthcare systems to address the issue of blood culture contamination. Magnolia Medical continues to develop, manufacture and market innovative blood sampling devices to enhance the dependability of crucial laboratory tests.